Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances. (February 2014)

• Record Type: Journal Article
• Authors: Matsangou, Maria; Santos, Edgardo S; Raez, Luis E; Gomez, Jorge E; Dinh, Vy; Savaraj, Niramol
• Is Part Of: Lung cancer management. Volume 3:Number 1(2014)
• Page Start: 85
• Page End: 99
• Publication Date: 2014-02
• Subjects: Lungs -- Cancer -- Periodicals; 616.99424
• DOI: 10.2217/lmt.13.64
• Languages: English
• ISSNs: 1758-1966

Abstract

SUMMARY Adjuvant cisplatin-based chemotherapy for early-stage non-small-cell lung cancer has become standard of care, after three recent meta-analyses validated survival benefit of approximately 5% at 5 years. Subgroup analyses, however, demonstrated that the benefit appears largely confined to patients with stage II disease; however, 25–30% of patients with stage I disease are at high risk of relapse and death within 5 years. Therefore, there is a need to predict more accurately which patients are likely to relapse after surgery and thus benefit from adjuvant therapy. Recent studies indicate that molecular biomarkers, gene-expression profiling and gene-mutation analysis may not only identify those tumors that are more likely to respond to adjuvant chemotherapy, but also to specific cytotoxic agents. These novel bioanalyses will allow physicians to deliver personalized medicine that utilizes cancer therapeutic drugs more cost effectively, thereby improving response rates and, hopefully, conferring survival advantage.